Charles Schwab Investment Management Inc. lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the ...

Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Arvinas Inc (NASDAQ:ARVN), a biotechnology company focused on developing therapies for cancer and other difficult-to-treat diseases, has been making waves in the pharmaceutical industry with its ...

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The ...

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of $97.00. The ...

Citi analyst Yigal Nochomovitz reiterated a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report) yesterday and set a price target of ...